Table 5 Variables used in model
From: Cost utility analysis of HIV pre exposure prophylaxis among men who have sex with men in Israel
Source(s) and numbered text References | |||
|---|---|---|---|
Intervention Costs | |||
PrEP daily first year | 24,143 | NIS | [57], b |
PrEP daily subsequent years | 23,565 | NIS | [57], b |
Current discount on PrEP cost | 10% | Assumed | |
Reduction for “PrEP on demand” | 40.1% | NIS | |
Monitoring PrEP first year | 4237 | NIS | a,b |
Monitoring PrEP subsequent years | 3659 | NIS | a,b |
Monitoring PrEP first year | 1810 | NIS | b |
Monitoring PrEP subsequent years | 1312 | NIS | b |
Employment Losses - first year | 1505 | NIS | |
Employment Losses - subsequent years | 1120 | NIS | |
Treatment Costs | |||
HIV Treatment Costs | 94,759 | NIS | d |
monitoring NON_HAART -first year | 5693 | NIS | a |
monitoring-NON HAART- subsequent years | 12,845 | NIS | a |
Disability Weights | |||
HIV negative (at age 36 years) | 0.09 | ||
HIV positive with HAART Rx | 0.14 | [18] | |
HIV no HAART Rx | 0.20 | [18] | |
AIDS with HAART Rx | 0.15 | ||
AIDS no HAART Rx | 0.29 | ||
Epidemiology | |||
Excess Hospitalization Days per HIV case | 1.74 | per year | [39], e |
HIV incidence rate trend among MSM (2011–2017) | −5.20% | per year | f |
HIV to AIDS progression with HAART | 0.08 | per year | |
HIV to AIDS progression without HAART | 0.33 | per year | |
HAART efficacy in Israel | 47.8% | 1 | |
% HIV+ taking HAART | 81.8% | f | |
% HIV+ of high risk group who will take HAART | 81.8% | f | |
% of persons who were not taking HAART who start taking when they get AIDS | 90% | f | |
Mortality Rates (%) per year | |||
HIV+ with ART- 40 yrs | 0.007 | ||
HIV+ with ART- 50 yrs | 0.013 | ||
HIV+ without ART- 40 yrs | 0.040 | ||
HIV+ without ART- 50 yrs | 0.073 | ||
AIDS+ with ART- 40 yrs | 0.060 | ||
AIDS+ with ART- 50 yrs | 0.067 | ||
AIDS+ without ART- 40 yrs | 0.524 | ||
AIDS+ without ART- 50 yrs | 0.587 | ||
PreP efficacy | |||
Baseline RCT | 86.0% | ||
sensitivity analysis | 78.5% | ||
sensitivity lower 90% | 56.3% | ||
sensitivity upper 90% | 90.0% | ||
open label trial | 97.1% | [10] | |
Coverage | 100% | Assumed | |
% of UAI MSM starting PrEP | 80% | [47] | |
% of non-UAI MSM starting PrEP | 25% | Assumed | |
% ofnon-UAI MSM PrEP who cease condom use | 75% | Assumption | |
Protection from condom use | 80% | ||
Transmission risk with condom | 1.6% | per act | |
Transmission risk without condom | 8.0% | per act | |
HIV cases per 100,000 high risk MSM | 421.8 | f | |
HIV cases per 100,000 non-high risk MSM | 84.4 | f | |
Demographic | |||
Average age at HIV diagnosis | 36.0 | Years | f |
Life expectancy at age of HIV diagnosis. | 45.6 | Years | [39] |
Male population aged 18–69 (2018) | 2,478,600 | [39] | |
MSM prevalence | 3% | [8] | |
MSM aged 18–69 | 78,013 | ||
Background Mortality - age-related eg: 40 yrs | 0.001064 | [39] | |
Background Mortality - age-related eg: 50 yrs | 0.002894 | [39] | |
Economic | |||
Discount Rate | 3% | per annum | [60] |
Average Employment Cost | 165,592 | NIS per annum | |
Exchange Rate | 3.595 | USD to NIS | [42] |
% makes 18–69 unemployed | 7.1% | [39] | |
Work losses due to PrEP monitoring yr 1 | 1505 | [39] | |
Work losses due to PrEP monitoring yr 2+ | 1120 | [39] | |
Productivity losses due to HIV | 23% | [38] | |
% participating in labour force (age-related) | 67–77% | ||
Burial Costs | 30,000 | NIS | Current cost |
General Hospital | 2218 | NIS per day | b |
Emergency Room Visit | 316 | NIS | b |
% work losses due to HIV aged 15–24 | 23.0% | [38] | |
% work losses due to HIV aged 25–53 | 32.2% | [38] | |
% work losses due to HIV aged 54+ | 4.6% | [38] | |
Absenteeism due to HIV treatment | 23.3 | hours per year | [38], e |
Social Overheads on wages | 23% | NIS | [38], e |
Wage Cost per Hour | 71.31 | [39] | |
Male working hours | 40.475 | hours per week | [37] |
GNP per capita | 145,374 | NIS | |